.jpg "Hu Li, PhD photo")
Sr. Director
Gilead Science Inc.
Hu Li, MBBS, PhD is a noted leader in pharmacoepidemiology at Gilead Science Inc.
Over decades of her professional career, Dr. Li has extensive experience in supporting clinical development throughout drug development life cycle in a number of therapeutics including cardiovascular, neuroscience, immunology, oncology and rare disease etc. Dr. Li has designed, conducted and published a number of high impact observational researches to highlight medication use, drug effectiveness and safety using real-world data. Dr. Li is an active contributor to scientific community, organizing workshop to develop methods and tools, interacting with regulatory agencies and other stakeholders. She is viewed as a champion of bringing cutting-edged real-world data and tools to help advance therapies in drug development.
